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1. Introduction
Stem cells, those elusive entities that have the capacity for producing, maintaining and
reconstituting the integrity of a biological system, also demonstrate the potential to predict
partial or life-threatening damage in response to drugs, environmental compounds and other
agents. It is ironic however, that in the animal or human, prior to the manifestation of such
potential biological damage most, if not all of the stem cells might have been eradicated. To
predict possible damage, surrogate in vitro stem cell assays have been developed that utilize
specific properties and characteristics that divulge, through a measured response, how the
system will react to different agents.
In  vitro  assays  that  detect  toxicity  to  stem cells  of  a  biological  system allow potentially
life-threatening  damage  to  be  predicted  prior  to  human  clinical  trials  taking  place  and
environmental  agents  from  causing  harm.  Discussions  about  stem  cells  usually  focuses
not  on  primary  cells,  but  rather  on  embryonic  stem (ES)  cells  and induced pluripotent
stem (iPS) cells, their ability to produce virtually any type of functional cell and their use
in cellular therapy and regenerative medicine. The ES and iPS types of stem cells are, in
fact,  the  least  understood  of  all  stem  cell  types.  For  many  companies  investigating  or
considering using these stem cells routinely as surrogate in vitro  models for toxicity test‐
ing many questions remain, including (1) what is the relevance of these cells, (2) how do
they  compare  with  primary  stem  cell  populations,  and  (3)  can  they  be  validated?  In
many cases, it is not the stem cells themselves, but rather the cells derived from ES and
iPS cells that are of interest. Several companies already produce ES- or iPS-derived cardi‐
omyocytes, hepatocytes, neural cells and many other cell types not only for toxicity test‐
ing, but also for basic research, cellular therapy and regenerative medicine.
How can stem cells  be used to predict  toxicity? The answer to this  question lies  in the
characteristics and properties of stem cells and how they respond to different situations.
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To understand this  better,  stem cell  systems can be divided into “definitive” and “non-
definitive”  systems  as  illustrated  in  Fig.  1.  Definitive  stem cell  systems  are  responsible
for maintaining a specific biological system. They can be divided into continuously pro‐
liferating systems such as the blood-forming or lympho-hematopoietic system, the gastro-
intestinal  system,  hair  and  skin,  reproductive  organs  and  cells  of  the  eye  cornea.
Although not necessarily a continuously proliferating system, the mesenchymal stem cell
(MSC), also called the multipotent mesenchymal stromal cell [1] system can been includ‐
ed, because in culture,  the MSCs proliferate and can be passaged over a long period of
time.  Definitive  stem cells  systems  can  also  demonstrate  partial  proliferation.  These  in‐
clude,  but  are  not  limited  to,  the  liver,  lung,  kidney,  heart,  pancreas,  and  the  neural/
neuronal  system. From a toxicological  viewpoint,  these are not  usually considered stem
cell systems. Yet, the different types of lineage cells present in these organs and the abili‐
ty to maintain a specific cell mass has all the intricacies of a stem cell system, especially
during development, even though the cell  turnover in the adult may be very low. Non-
definitive stem cells systems are represented by the ES and iPS cell  systems, which can,
theoretically, give rise to any of the definitive stem cell systems. Indeed, it is a prerequi‐
site  that  the  production  of  functionally,  mature  cells  from  ES  or  iPS  cells  first  pass
through a definitive stem cell compartment.
2. Stem cell characteristics and properties used for toxicity testing
Stem cells of primary, definitive systems always represent a very small proportion of the tissue
or organ cellularity. This proportion is between 0.1 and 0.01% or less. The basic definition of
a stem cell is that it possesses the capacity for self-renewal. In fact, stem cell systems are usually
termed self-renewal cell systems, meaning that one stem cell can produce two daughter cells
that are exact replicas of the parent. However, self-renewal is a difficult property to measure.
The capacity for either serial in vivo repopulation or in vitro serial re-plating is considered a
property of stem cells that implicates not only the presence of stem cells, but also their self-
renewal capability. The fact that serial in vitro re-plating or in vivo repopulation cannot be
performed ad infinitum is not only an indication for a stem cell hierarchy [2-7], but also for an
alternative hypothesis to stem cell self-renewal. This hypothesis states that tissues and organs
are endowed with a specific number of stem cells. Once used up, the system ceases to function
[8]. Regardless of the hypothesis, this important property can be utilized in a toxicological
setting by employing secondary re-plating technology. This allows not only the presence of
residual stem cells to be detected that have not been affected by a compound, but any change
in sensitivity to a compound that might be important during repeated dose administration.
Stem cells have two other important properties that can be applied to toxicity testing. The
first is that they are undifferentiated. The second is that stem cells proliferate. Stem cells can
be “determined” into one or more lineages of mature functional cells. When a stem cell be‐
comes determined, it ceases to be a stem cell and becomes a progenitor cell that proliferates
and differentiates. The fact that stem cells can be induced to differentiate means that what‐
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ever happens at the stem cell level will ultimately affect all downstream events. These char‐
acteristics enable stem cells to be the most important predictors of potential toxicity.
Figure 1. Definitive and Non-Definitive Stem Cell Systems. Definitive stem cell systems can be further divided into
continuously and partially proliferating systems. Non-definitive stem cell systems such as embryonic stem cells and in‐
duced pluripotent stem cells can produce definitive stem cell systems, which in turn, give rise to mature functional
cells.
All definitive stem cell systems have a common organization shown in Fig. 2. There is a
continuum of stem cells within the stem cell  compartment that exhibit  different degrees
of primitiveness or “stemness”, which in turn, implies changing proliferating potential or
potency  as  a  stem  cell  moves  through  the  compartment  to  the  point  of  determination.
These characteristic properties actually provide the information that allows stem cells to
be predictors of potential  toxicity.  Once a stem cell  becomes a progenitor cell,  prolifera‐
tion continues and actually increases for  a  certain time so that  the compartment can be
amplified,  until  it  ceases  completely  and  the  differentiation  and  maturation  processes
takes  over.  These  changes  have  important  implications  for  the  types  of  assays  that  can
be used in vitro to detect potential toxicity.
From Fig. 2, it is clear that proliferation occurs prior to differentiation. Although there is
considerable overlap between proliferation and differentiation, they are two separate proc‐
esses that cannot be measured using the same assay readout. Since stem cells only proliferate,
it follows that a proliferation assay is required to detect the presence and response of stem cells
to a compound or agent. Using a differentiation assay to detect the effect of a compound or
agent that targets one or more steps in the proliferation process can influence the interpretation
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and conclusion of the results. This can have far-reaching consequences on the decision to move
forward with the development of a new drug candidate.
Figure 2. The Common Organization of Definitive Stem Cell Systems
Toxicity represents between 30-40% of the drug attrition rate [9,10]. It is therefore not sur‐
prising that biopharmaceutical companies are eager to employ assays that allow early pre‐
diction of toxicity prior to starting human clinical trials. Once the drug discovery phase has
been concluded, the drug development phase begins (Fig. 3) by screening thousands of com‐
pounds in a battery of tests to determine absorption, distribution, metabolism and excretion
(ADME) as well as preliminary toxicity (ADME/Tox). Many of the ADME/Tox assays as
well as those in the lead optimization phase use transformed cell lines as cell targets, such as
the NCI60 cell line panel [11,12]. Once these tests have whittled down the number of possi‐
ble drug candidates, pre-clinical animal models are used. Neither cell lines (even if they are
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of human origin) nor animal testing provide good extrapolation to the human situation. It is
not uncommon for unexpected results or toxicity to rear its head during animal studies be‐
cause of the lack of predictive information obtained during previous screening and testing
[13]. Many published articles have dealt with this problem, one of the most notable being
the monograph on Toxicity Testing in the 21st Century [14]. Despite the goals of the drug
development pipeline and the considerable effort being undertaken by regulatory agencies
[15-20] to determine the effect of environmental agents on human cells, interpretation and
conclusions often fall short due to lack of understanding of the mechanism of action of the
molecule, incorrect assay readout and/or incorrect target cell, to name but a few reasons. If
the goal is to determine the effect on human cells, then mouse, rat, dog or even non-human
primate cells will not provide the required information; human cells must be used. It goes
without saying that drug development or testing xenobiotic agents cannot be performed on
human subjects. It is for this reason why surrogate in vitro assays using primary human cells
obtained from donors under the auspices of regulatory controlled internal review boards
(IRBs) provide the best alternative. However, even under these circumstances, detailed
knowledge of the biological system under study is necessary in order to interpret and make
conclusions in the most objective manner.
Of all the biological systems of the body, the one most studied is also one of the systems that
is given the least priority with respect to toxicity. The blood-forming or hematopoietic system
and the gastrointestinal system are two continuously proliferating systems that are expected
to be dramatically affected by anti-proliferating agents such as anti-cancer drugs. As a result,
the only relevant questions are (a) how severe would toxicity be, and (b) would use of the drug
provide a favorable therapeutic index?
Figure 3. The Major Stages of the Drug Development Pipeline
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Hemotoxicity testing is traditionally performed during the last stage of drug development,
namely pre-clinical animal testing. Circulating blood parameters are measured and at
necropsy, bone marrow, spleen and even liver hematopathology are performed. Primary stem
and progenitor cells cannot be morphologically identified. Morphological identification of
cells is only possible once the cells start to differentiate and mature. Consequently, traditional
hemotoxicity testing provides little, if any, predictive value since most of the toxic effects have
occurred on more primitive cells.
Much of our knowledge about the characterization, properties and responses of hematopoietic
stem cells and the system as a whole has been provided through the use of drugs and other
agents (e.g. radiation) using both in vivo and later, in vitro assays. The information obtained
has allowed the organization and hierarchy within the different compartments of the hema‐
topoietic and lymphopoietic systems to be elucidated. By utilizing the knowledge that has
accrued over more than six decades, analysis of the lympho-hematopoietic stem and progen‐
itor cells provide the highest degree of predictive toxicity of any biological system.
3. The Colony-Forming Cell (CFC) assay and ECVAM studies
In 1966, Bradley and Metcalf in Melbourne, Australia [21] and Pluznik and Sachs in Rehovot,
Israel, [22] independently published what is now known as the colony-forming unit (CFU) or
colony-forming cell (CFC) assay. In its original form, mouse bone marrow target cells were
suspended in agar containing a conditioned medium that we now know contained granulo‐
cyte-macrophage colony stimulating factor or GM-CSF as well as other soluble factors. In the
semi-solid medium, the cells underwent proliferation and later differentiation to produce
colonies of cells that were identified either as neutrophils, macrophages or a combination of
the two cell types. The number of colonies counted under an inverted microscope was
proportional to both the number of cells plated and the dose of the conditioned medium added.
In the same year, Cole and Paul [23] in Glasgow, Scotland reported the first in vitro suspension
culture of murine erythropoietic cells from the yolk sac and fetal liver. Culture of erythropoietic
cells under clonal conditions did not occur until 1971, when the Axelrad group [24] in Toronto,
Canada, demonstrated that erythroid colonies could be produced using a plasma clot techni‐
que. In 1974, Iscove and colleagues [25] in Basel, Switzerland introduced the methylcellulose
CFC assay that is still used today. Since that time, colony assays have been developed to detect
multiple cell populations of every blood cell lineage, including several different stem cell
populations. In addition, conditioned media has been replaced with recombinant growth
factors and cytokines.
In Section 2, emphasis was placed on the importance between proliferation and differentiation.
The cell populations detected using the CFC assay must all be proliferating populations,
otherwise the production of colonies would not occur. However, to identify the type of colony,
the in vitro culture must be allowed to proceed long enough so that the cells produced can
themselves be identified as being derived from a morphologically unidentifiable stem,
progenitor or precursor cell, all of which are capable of proliferation, but to different extents.
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As mentioned above, although proliferation is required to produce colonies, the number of
cells produced as a quantitative measure of proliferation cannot be ascertained. Although
proliferation is assumed, the CFC assay actually detects differentiation ability or potential.
This has important consequences for toxicity testing.
Over several years, the European Center for the Validation of Alternative Methods (ECVAM)
undertook a series of studies in which a number of drugs and chemicals were tested using the
CFC assay. These studies are noteworthy because they represented the first attempt to validate
a prediction model for assessing the maximum tolerated dose (MTD, equivalent to the IC90
value) for drugs that induce neutropenia [26,27] using the CFC assay. The studies were
performed in different laboratories and were later extended to compounds that caused
thrombocytopenia [28]. Potential neutropenia was detected by the effect on the granulocyte-
macrophage colony-forming cell or GM-CFC (also called CFC or CFC-GM), while thrombo‐
cytopenia was detected by the effect on the megakaryocyte colony-forming cell or Mk-CFC
(also called CFC-Mk). A decrease or inhibition in the number of colonies counted derived from
GM-CFC or Mk-CFC predicted a reduction in neutrophils or platelets in the circulation. The
authors demonstrated that the model could correctly predict the MTD of 20 out of 23 drugs
tested (87% predictive rate).
There are two points worth emphasizing. First, not all compounds will produce an estimated
IC90 value and may not even produce an IC50 value, when tested using the CFC assay. Does
that mean that these compounds will not produce neutropenia or thrombocytopenia? It is
interesting to note that the same CFC assay that is used to predict toxicity causing neutropenia
or thrombocytopenia, is also used in an opposite manner to predict time to neutrophil or
platelet engraftment after bone marrow, mobilized peripheral blood or umbilical cord blood
stem cell transplantation for cellular therapy [39-31]. In either case, the GM-CFC or MK-CFC
populations provide no information on the response of the more sensitive and more important
stem cells. After all, it is the hematopoietic stem cells that give rise to both of these populations.
This leads to the second point, namely that many compounds target one or more steps in the
proliferation process, either at a molecular and/or cellular level. Although both GM-CFC and
Mk-CFC populations are proliferating progenitor cell populations, they are not always the
primary targets. When a compound affects more than one lineage, the primary effect is not on
those lineages individually, but on the common cell that gives rise to those lineages, namely
the stem cells [32]. From a practical viewpoint, however, the CFC assay posses daunting
problems. The ECVAM studies summarized previously were exceptional in that the authors
took the trouble to try and verify and standardize the readout of the assay that is inherently
subjective and lacks the necessary external standards and controls by which the assay could
be properly validated. In studies performed by the National Marrow Donor Program (NMDP),
the results showed very high variability in CFU colony counting for cord blood [33]. This high
variability, primarily due to the inaccuracy of dispensing methylcellulose and colony counting,
together with the lack of high throughput capability does not provide the biopharmaceutical
industry, environmental agencies or other areas of toxicology, risk or efficacy assessment with
a routine and trustworthy assay platform. To negate all of these problems, the HALO Predic‐
tive Hemotoxicity Platform was developed.
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4. Predictive stem cell hemotoxicity testing
Whereas the CFU assay may be used to predict neutropenia, thrombocytopenia, anemia and
the MTD indicated by the IC90 values [27-29], stem cells assays allow potential hemotoxicity
to be taken to a different system-wide “global” level. The reason is provided in Fig. 2 and in
more detail in Fig. 4, which shows the different lympho-hematopoietic cell populations that
can be detected using a hemotoxicity screening and testing platform specifically developed
for this purpose. This platform, called HALO, will be described in more detail in the next
section. Figures 2 and 4 demonstrate that functionally mature cells from definitive continu‐
ously proliferating and partially proliferating cell systems, are derived from stem cells. As
such, any perturbation or damage to the stem cell compartment will ultimately affect all
downstream cell populations. In other words, examining the effect on stem cells allows the
“global” effect on the system to be predicted. Since more is known about the organization,
hierarchy and regulation of the lympho-hematopoietic system than probably any other
biological system in the body, this knowledge can be used to predict and explain potentially
deleterious effects to the system. Changes in the response to hematopoietic stem cells will affect
all three primary hematopoietic lineages, namely the erythropoietic, myelomonocytic and
magakaryopoietic lineages. Changes in the response to lympho-hematopoietic stem cells, i.e.
those stem cells that can give rise to both the lymphopoietic and hematopoietic cells, will be
expected to affect most, if not all cell lineages, including the T- and B-cell lineages and therefore
the immune system as a whole.
Predictive stem cell hemotoxicity testing is not simply the estimation of IC values so that
compounds can be ranked in order of toxicity to different cell populations or species. There
are several other important applications in which stem cell hemotoxicity, and indeed stem cell
toxicity in general, can be used. Examples of these applications will be discussed later in this
chapter. First, however, it is necessary to describe the principles, characteristics and properties
of the assay that make this possible.
5. Materials and methods
HALO is the acronym for Hematopoietic/Hemotoxicity Assays via Luminescence Output.
This platform was originally designed and developed to provide the biopharmaceutical in‐
dustry with a high throughput, validated assay to examine the effects of virtually any com‐
pound on different cell populations of the lympho-hematopoietic system from multiple
species. Initially, the assay platform was developed for fresh, primary human cells, as a sur‐
rogate assay that could be used at virtually at stage in the drug development pipeline (Fig.
3) to extrapolate to the human situation, and as an alternative to pre-clinical animal studies.
The platform has since been further developed to include non-human primate, horse, pig,
sheep, dog, rat and mouse, not only for toxicity studies, but also for basic research and vet‐
erinary applications.
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Figure 4. The Organization and Hierarchy of the Lympho-Hematopoietic System as a Model for a Definitive Continu‐
ously Proliferating Stem Cell System. The properties of stem cells play an integral part in predicting toxicity.
5.1. Concepts and principles of the HALO platform
When cells  proliferate  or  are  inhibited from proliferation by  drugs  or  other  agents,  the
concentration  of  intracellular  adenosine  triphosphate  (iATP)  changes  proportionately.
This biochemical marker is an indicator of cellular and mitochondrial integrity and there‐
fore viability of the cells. Indeed, iATP is used as a metabolic viability assay (as opposed
to a dye exclusion viability assay). Under normal conditions, stimulation of cell prolifera‐
tion  requires  specific  growth  factors  and/or  cytokines  either  alone  or  in  combination
(cocktails). For continuously proliferating systems, growth factors or cytokines need to be
present  continuously,  albeit,  in  very small  concentrations,  in  order  to  maintain cell  sur‐
vival and production. Thus, to detect the effect of any agent on hematopoietic cells in vi‐
tro,  the  target  cell  population must  be  stimulated in  order  to  detect  changes  in  the  cell
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population response to the agent. The agent is usually added in a dose-dependent man‐
ner to the target cells, which are then incubated for a specific period of time. Thereafter,
the cultures are removed from the incubator and the cells lysed to release the iATP. The
latter then becomes a limiting substrate for a luciferin-luciferase reaction to produce bio‐
luminescence in the form of light as shown in the equation below.
iATP + Luciferin + O2 →Mg2+
Luciferase
Oxyluciferin + AMP + PPi+ CO2+LIGHT
The light is measured in a plate luminometer. The amount of light produced correlates directly
with any change in the iATP concentration and therefore with the state of proliferation or
inhibition of the cells.
5.2. Cell sources
Cells from any hematopoietic or lymphopoietic organ can be used. For most of the studies
described here, fresh or cryopreserved human bone marrow or peripheral blood cells were
collected with prior authorization by an Internal Review Board (IRB). Human cells were
obtained from Lonza (Walkerville, MD) or Allcells (Berkely, CA). A mononuclear cell (MNC)
fraction was prepared using density gradient centrifugation. A nucleated cell count was
performed using a Z2 particle counter (Beckman Coulter), while dye exclusion viability was
performed using 7-aminoactinoycin D (7-AAD) and flow cytometry. Metabolic viability was
performed using LIVEGlo (HemoGenix, Colorado Springs, CO).
5.3. Cell culture
For all toxicity studies, MNC were diluted so that the final cell concentration was either
7,500  or  10,000  cells/well.  Either  96-well  or  384-well,  solid  white-wall  plates  were  used
and all  dispensing was performed using a liquid handler (Beckman Coulter,  EPICS XL-
MCL). After the cell suspension was prepared, it was added to a Master Mix containing
reagents including growth factors and/or cytokines to stimulate the target cell population
being studied. Five different hematopoietic stem cell populations have so far been devel‐
oped for  this  assay,  the  most  important  being  the  Colony-Forming  Cell  –  Granulocyte,
Erythroid,  Macrophage,  Megakaryocyte  or  CFC-GEMM  (referred  to  in  Fig.  4  as  CFC-
GEMM 1).  This  particular  stem cell  population is  stimulated with erythropoietin (EPO),
granulocyte-macrophage  and  granulocyte  colony  stimulating  factors  (GM-CSF,  G-CSF),
Interleukins 3 and 6 (IL-3, IL-6), stem cell factor (SCF), Flt3-Ligand (Flt3-L) and thrombo‐
poietin (TPO).  Compared to a “classic” CFC assay,  HALO does not incorporate methyl‐
cellulose and is  therefore not  a  clonal  assay.  Instead HALO uses Suspension Expansion
Culture  (SEC)  Technology,  which  has  several  advantages  over  methylcellulose  assays.
First,  SEC assays  allow more accurate  dispensing using liquid handlers.  This  is  in  con‐
trast  to  inaccurately  dispensing  methylcellulose  with  syringes  and  needles.  Second,  the
use of liquid handlers allows for true high throughput capability with accurate dispens‐
ing even in 384-well  plates.  Third, as opposed to methylcellulose,  where little or no cell
interaction occurs, SEC technology allows cells to interact with each other. This has two
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important consequences.  Cell  interaction reduces the time for the onset of  cell  prolifera‐
tion  by  approximately  24  hours.  This  means  that  measurement  of  cell  proliferation  can
be  measured  within  5  to  7  days.  Indeed,  for  all  of  the  studies  described  here,  human
cells  were incubated for 5 days.  Non-human primate cells  are usually incubated for the
same time, but all other animal cells only require 4 days of incubation. The second con‐
sequence of allowing cell interaction to occur is the two-fold increase in assay sensitivity.
As with most cell  cultures,  cells are incubated at 37ºC in a fully humidified atmosphere
containing  CO2.  Incubating  cells  under  low oxygen tension  of  5% O2,  which  is  approx.
equivalent to the venous oxygen tension, reduces oxygen toxicity due to free radical pro‐
duction and improves plating efficiency [34,35] for all lympho-hematopoietic cell popula‐
tions as well as other cell types.
5.4. Controls and dosing
Four basic controls were always included for toxicity studies. A background control included
cells, but no growth factors. A vehicle control was similar to the background control, but
included the vehicle used to dissolve the compound. Growth of the target cell population
without any compound or vehicle constituted the growth factor control. A similar control that
included the vehicle was designated the growth factor + vehicle control. Drugs and other
agents were investigated over 6 – 9 doses.
5.5. Instrument calibration, assay standardization and sample processing
Prior to measuring any sample, the instrument was calibrated and the assay standardized
using an external ATP standard and controls. The procedures have been described previously
[32] and detailed procedures can also be obtained [36,37]. Calibration and standardization
were also part of the assay validation process (see Section 5.6).
There are other advantages for calibrating and standardizing the assay.  First  results can
be compared over time. Second, the output of a plate luminometer is  in Relative Lumi‐
nescence  Units  or  RLU.  The  results  are  relative  because  different  instruments  demon‐
strate  different  ranges  of  RLU.  These  ranges  may  vary  from  0  to  100  for  one
manufacturer or 0 to several million for another. This means that it would be very diffi‐
cult  to directly compare results within and between laboratories using RLU values.  Per‐
forming  an  ATP  standard  curve  allows  all  the  results  to  be  interpolated  from  RLU
values into standardized ATP concentrations (μM).
5.6. Assay verification and validation
HALO was originally developed from the “classic” CFC assay because the latter was the
only  cell-based  assay  that  could  detect  primitive  hematopoietic  cell  populations.  Since
HALO is  a  proliferation  assay,  while  the  CFC detects  differentiation  of  the  same cells,
and  because  proliferation  occurs  prior  to  differentiation,  it  follows  that  one  assay  can
verify  the  other.  Indeed,  several  publications  have  shown  a  direct  correlation  between
the two assays [32,38,39].
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Validation, on the other hand, is quite a different matter. Assay validation is defined as
“establishing documented evidence which provides a high degree of assurance that a specific
process will consistently produce a product meeting its predetermined specifications and
quality attributes” [40]. When an assay is properly validated the accuracy (proportion of correct
outcomes), sensitivity (proportion of correctly identified positive samples), selectivity (pro‐
portion of correctly identified negative samples), precision (intra and inter-laboratory varia‐
bility) and robustness (the ability of the assay to withstand changes and transferability) all
combine to give the user the assurance that the results obtained are correct. The ECVAM
studies described in Section 2 above were, and still are, the closest the CFC assay has come to
being validated. There have been many attempts to validate the CFC assay, but all have failed.
Certainly the assay has shown, from a subjective viewpoint, some of the attributes. However,
since there are no standards and controls by which the CFC assay can provide documented
and quantitative evidence for each of the required parameters, the assay has never been
properly validated. Like many assays that have been used for decades, the CFC assay has been
“grandfathered” in and used despite the problematic trustworthiness and meaning of the
results obtained [33,37].
HALO, from the outset, was designed to be validated. The assay was developed to incorporate
the range values specified in the FDA Guidance on Bioanalytical Method Validation [40]. In
summary, these values are as follows:
• Assay linearity: => 5 logs.
• Assay cell linearity: 1,000 - > 25,000 cells/well.
• Assay ATP sensitivity: ~ 0.001μM.
• Assay cell sensitivity: 20-25 cells/well, depending on cell purity).
• Accuracy: ~95%.
• Sensitivity & Selectivity by Receiver Operator Characteristics (ROC): Area Under Curve
(AUC) 0.73 – 0.752 (lowest possible value: 0.5; highest possible value, 1).
• Precision: = < 15%. Lower limit of quantification (LLOQ): 20%.
• Robustness: ~95%.
• High throughput capability (Z-factor [57]): > 0.76.
• Log-log linear regression slope for ATP standard curve: 0.937 ± 15% (slope range: 0.796 –
1.07)
• Lowest ATP value indicating unsustainable cell proliferation: ~ 0.04μM.
• ATP value below which cells are not metabolically viable: ~0.01μM.
In addition, the assay has also been validated against the Registry of Cytotoxicity Prediction
Model, which will be discussed in more detail in Section 5B.
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5.7. Statistics
All of the results provided were produced using 8 replicate wells/point. Compound dose
response curves were fitted to a 4- or 5-parameter logistic curve fit using SoftMax Pro software
(Molecular Devices) from results exported directed from the plate luminometer and calculated
automatically. To estimate IC values, raw data were converted to a percentage of the growth
factor + vehicle control. Additional statistics, curve fitting or graphing was performed using
Prism software (GraphPad) or OriginPro (OriginLab).
6. Results and discussion
6.1. Distinguishing the response of stem cells from progenitor cells
From a practical viewpoint, stem and progenitor cells are distinguished by at least two different
characteristics. First, stem and progenitor cell populations are stimulated using different
cocktails of growth factors and cytokines. In this way, specific cell populations can be targeted
and studied, even though the cell suspension may contain other cell types. Combined with the
culture conditions, this allows detection and measurement of specific cell populations. The
other distinguishing characteristic is the difference in proliferation ability and potential
between stem and progenitor cells. Even within the stem cell compartment, differences in
proliferation potential will indicate the primitiveness or “stemness” of populations. This
characteristic is shown in Fig. 5 for normal bone marrow cells. Since the stem cells are more
primitive than the progenitor cells, it would be expected that their proliferation potential
would be greater. Figure 5 shows that the two stem cell populations exhibit, not only greater
ATP concentration values, but also greater linear regression cell dose response slopes than the
hematopoietic or lymphopoietic progenitor cells. It is the slope of the cell dose response that
measures proliferation potential. The greater the slope, the higher the proliferation potential,
and the more primitive the cell population. Indeed, this is the basic principle for measuring
potency of hematopoietic stem cell therapeutic products for transplantation [37]. In this way,
it is possible to distinguish different stem cell populations, in this case the hematopoietic stem
cell, CFC-GEMM 1, from the more primitive lympho-hematopoietic stem cell, HPP-SP (high
proliferative potential – stem and progenitor cell). The HPP-SP stem cell will be discussed in
more detail in Section 6.4. The three cell dose response clusters showing the differences in
proliferation potential in Fig. 5 for stem cells, hematopoietic progenitor cells and lympho‐
poietic progenitor cells would be expected based on the organization of the blood-forming
system shown in Fig. 4. Figure 6 demonstrates the expected proliferation ability of the seven
different cell populations in response to mitomycin-C, with the stem cells showing the greatest
ability to proliferate followed by the three hematopoietic lineages and lymphopoietic lineages.
The steepness of the linear regression slope of the cell dose response for a cell population
provides a measure of the proliferation potential. Stem cells exhibit the greatest proliferation
potential of all cells. Within the stem cell compartment, stem cells with different potentials
for proliferation also indicate their primitiveness. Proliferation ability is measured at a single
cell dose (see Fig. 6).
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Figure 5. Measuring Proliferation Potential of Cell Populations

Figure 6. Demonstration of Proliferation Ability between Cell Populations
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6.2. Drug and compound screening for stem cell toxicity
In its most basic form, a single drug or compound is tested in a dose dependent manner on a
target cell population. If the agent is cytotoxic to the cells, a negative sigmoidal dose re‐
sponse (Fig. 6) will result from which the estimated percent inhibitory concentrations (IC)
can be calculated. Figure 7 shows the dose response curves from 13 drugs and compounds
tested on hematopoietic stem cells (CFC-GEMM 1) derived from fresh, human bone marrow
using the MNC fraction. Although different cell types are included in this fraction, stimula‐
tion of this particular stem cell population using a specific growth factor cocktail provides
the relevant information. For each of the compounds tested a 4-parameter logistic curve fit
was plotted from which the IC values could be calculated. Table 1 shows all of the com‐
pounds ranked in order of IC50 (μM) value from the most to the least toxic. The IC90 value
(equivalent to the maximum tolerated dose, MTD) is also provided. Many of the compounds
tested were also used in the ECVAM studies [26,27].
Table 1 shows some compounds designated as NV or NE. The term NV indicates that an
IC20 values was obtained, but no IC50 or IC90 value. The term NE means “no effect” in that
no IC values could be estimated. As a result, methotrexate, which is an anti-cancer agent
and expected to produce a more dramatic effect on stem cells, is actually ranked near the
end of the list. Furthermore, compounds that do not allow an IC value to be calculated
might actually produce some effect. The problem with ranking compounds based on their
IC values is that it does not take into account the “form” of the dose response curve, which
can actually provide more information than the IC value alone. Figure 7 shows a large num‐
ber of different dose response curves. One of the most important parameters provided by
the 4-parameter logistic curve fit is coefficient or parameter B, which describes the transition
of the curve to the midpoint of the dose response. This is a measure of steepness or slope. In
some cases the slope is shallow, while in other cases it is almost vertical. How can this and
other parameters of the dose response curve be taken into account so that they are inde‐
pendent of the IC value? The answer lies in calculating the area under the curve (AUC) for
the range of doses used. When the AUC is performed and plotted so that the compounds are
ranked, a different and more plausible picture is obtained (Fig. 8).
In this case, the AUC values for both stem cells (CFC-GEMM 1) and granulocyte-macro‐
phage  colony-forming  cells  (GM-CFC)  are  shown.  When  the  results  for  CFC-GEMM  1
are compared with those in Table 1, the results generally follow the IC50 values. Howev‐
er, the toxicity of methotrexate is significantly increased and cycloheximide is more toxic
than  paclitaxel.  The  results  for  the  GM progenitor  cells  have  been  included to  demon‐
strate  that  progenitor  cells  exhibit  lower  toxicities  than  stem  cells.  Unless  there  is  evi‐
dence  to  demonstrate  that  a  compound  acts  on  a  specific  hematopoietic  lineage,  it  is
more prudent to analyze potential toxicity to the stem cell compartment first, rather than
focusing  on  a  particular  lineage,  since  the  latter  will  only  provide  limited  information
that could possibly result in a false interpretation and conclusion.
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Figure 7. The Effect of 13 Compounds on Hematopoietic CFC-GEMM Stem Cells. Diagram showing the dose response
plots produced automatically by SoftMax Pro software after the data was collected by the SpectraMax L plate lumin‐
ometer. The parameters that define the 4-parameter logistic curve to which the dose responses of the compounds are
fitted are as follows: Parameter A, asymptote (flat part of the curve) at low Y-values; Parameter D, asymptote at the
highest Y-values; Parameter or coefficient B, the transition from the asymptotes to the center of the curve; Parameter
or coefficient C, is the midpoint between parameters A and D, also called the IC50 or EC50. Data that cannot be prop‐
erly fitted will result in ambiguous results.
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Compound Effect Rank IC50 (μM) IC90 (μM)
Camptothecin Anti-cancer 1 0.02 0.14
Paclitaxol Anti-cancer 2 0.18 4.81
Cycloheximide Pesticide 3 0.23 0.86
Cyclosporin A Immunosuppressant 4 2.57 8.2
5-Fluorouracil Anti-cancer 5 5.79 29.7
Chlorpromazine
(Thorazine) Anti-psychotic 6 5.88 7.03
Rifampicin Anti-bacterial 7 12.8 NV
Zedovuidine(AZT) Anti-viral 8 30.4 NV
Choramphenicol Anti-bacterial 9 94.7 NV
Indomethacin Anti-inflammatory 10 394.2 947.5
Methotrexate Anti-cancer 11 NV NV
Acyclovir Anti-viral 12 NE NE
Warfarin Anti-coagulant 13 NE NE
NV indicates No Value for these IC values. An IC20 value would have been estimated by the software program.
NE indicate No Effect. In this case, the dose response for the compound did not produce an IC values.
Table 1. Ranking of Stem Cell Toxicity According to IC50 Values
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Figure 8. Ranking of Stem Cell and Granulocyte-Macrophage Progenitor (GM-CFC) Toxicity According to the Calculat‐
ed Area Under the Curve (AUC) for the Dose Responses shown in Figure 7.
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6.3. The registry of cytotoxicity prediction model [41]
The Registry of Cytotoxicity (RC) is a list  of 347 compounds, for which the IC50 values
using a neutral  red uptake assay for human keratinocytes and mouse 3T3 cells  and the
oral LD50 values for rat or mouse, are known. When validating an in vitro  assay against
the RC,  a  sample of  reference compounds is  tested.  The resulting IC50 values from the
in vitro assay are then plotted against the LD50 values for the same compounds. A linear
regression  should  be  obtained  exhibiting  equation  constants  within  a  specific  range.  If
this occurs, the in vitro assay is considered a validated cytotoxic test. The results validat‐
ing HALO against the RC Prediction Model were first reported in 2005 [33].  One of the
most interesting aspects of this prediction model is that once an assay has been validat‐
ed, it  can be used to convert in vitro  IC values into clinically relevant doses that can be
used as starting doses for pre-clinical  animal models or human clinical  trials.  An exam‐
ple  of  this  is  shown  in  Table  2  where  the  results  of  converting  IC20,  IC50  and  IC90
range values derived from the effects of  18 compounds on CFC-GEMM 1 bone marrow
cells  is  shown. The predicted doses derived from the IC values are given in both milli‐
grams/kilogram (mg/kg) and milligrams/meter2  (mg/m2). Doses used in the clinic to treat
patients are also shown in mg/kg or mg/m2  where available.  With the exception of  two
drugs,  namely  acyclovir  and warfarin,  nearly  all  of  the  doses  predicted  by  the  in  vitro
CFC-GEMM 1 assay using ATP bioluminescence are in the same order of magnitude or
very close to the doses used to treat patients. In some cases lower doses were predicted
(e.g. 5-fluorouracil), while in other cases slightly higher doses were predicted (e.g. cyclo‐
sporine A,  indomethacin,  cisplatin and mitomycin-C).  Thus these predicted starting val‐
ues may be used in early toxicity and efficacy studies to “bracket” the lower and higher
dose ranges.
6.4. Residual stem cells after toxicity
Figure 7 shows that the response of stem cells to toxic agents can vary dramatically. In some
cases, agents cause complete eradication of all stem and progenitor cells at high doses. In other
cases, there is partial cytotoxicity at which, even at high doses, stem and progenitor cells are
not eradicated. This is an indication that some stem cells survive or are possibly resistant to
the drug or compound. If stem cells are not noticeably affected at high doses, there is a good
chance that when the drug or compound is removed, the system will reconstitute itself. If no
stem cells are available, this will not occur. However, there are other aspects to this phenom‐
enon that are important.
Primitive stem cells are usually in a quiescent state; they are not proliferating and therefore
not in cell cycle. This does not mean that they cannot be affected by an agent. Small molecules
can enter a cell even if it is quiescent. When required to initiate the proliferation process and
begin cell division, the process may be aborted because the agent inhibits the process. This is
a potential dangerous situation for two reasons. First, the “backup plan” for reconstituting the
system may not function. Second, if cells do begin to proliferate and divide, they may be more
sensitive to the agent. The consequence of this is that repeated administration of the drug or
compound will continually reduce the proportion of residual stem cells present.
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Predicted Dosing Range from In Vitro
Stem Cell Assay
Published Drug Doses Used to Treat
Patients
Drug/Compound Dose in mg/kg Dose in mg/m2 Doses or Dose Rangein mg/kg
Doses or Dose Range
in mg/m2
Doxorubicin 2.6 – 6.9 97 – 255 25/50/60/75
Daunorubicin 0.5 – 2.6 19.6 – 97 30/45/60
5-Fluorouracil 2.0 – 7.0 79 – 259 400 – 2,600
Paclitaxel 2.0 – 17.5 72 – 647 75 – 250
Imatinib (Gleevec) 3.6 – 30.5 132 – 1,125 400/600
Methotrexate 5.8 215 10 – 8,000
Cyclosporin A 14.2 – 31.2 524 – 1,155 5 – 10
Indomethacin 32 – 73 1,190 – 2,700 0.2 – 2
Zedovudine (AZT) 4.3 – 12.2 161 – 452 1 – 7.4
Chlorpromozine
(Thorazine) 6.8 – 7.7 253 – 285 1 – 4.5
Acyclovir NV NV 5 – 500
Camptothecin 0.36 – 1.52 13.3 – 56 25/320/470
Choramphenicol 16 – 24 594 – 896 12.5/30 – 50
Rifampicin 24 – 26 894 – 955 10
Warfarin NV NV 0.1 – 5
SJG-136 0.1 – 0.3 4 – 10 6 – 40
Cisplatin 6.3 – 9.8 233 – 363 30 – 100
Mitomycin-C 1.2 – 6.0 47 – 220 6/10 – 20
The IC values obtained from the validated in vitro assay are entered into the equation: Y = 0.435 * Log (IC value) + 0.625
[41]. The dose in mg/kg is then obtained by multiplying the value for Y with the molecular weight of the compound. The
dose in mg/m2 is obtained by multiplying the dose in mg/kg by a specific factor described in [42].
Table 2. Using the Registry of Cytotoxicity Prediction Model to Convert In Vitro IC Values into Clinically Relevant
Starting Doses
To demonstrate this, we developed an in vitro secondary re-plating assay for primitive stem
cells called high proliferation potential – stem and progenitor cells (HPP-SP). This stem cell
population, within the stem cell compartment (Fig. 4), is approximately at the divergence of
the lymphopoietic and hematopoietic systems. The majority of HPP-SP stem cells are quies‐
cent. They can be induced or “primed” into proliferation with IL-3, IL-6, SCF and Fl3-L. This
stem cell population is designated HPP-SP 1. Once the HPP-SP 1 cells begin proliferation, they
can be expanded with a similar cocktail of growth factors and cytokines to that for CFC-GEMM
1, but with the addition of interleukins 2 and 7 (IL-2, IL-7). This fully stimulated primitive stem
cell population is designated HPP-SP 2. In this two-stage assay, the HPP-SP 1, present in the
MNC fraction of bone marrow are cultured in the presence of the drug or compound in a dose-
dependent manner. Thereafter, the cells are removed from culture, washed and re-plated in a
secondary culture system in which the HPP-SP 2 population is measured. By performing a
secondary re-plating step, the assay is substantiating the presence of primitive stem cells
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present in the first “priming” step of culture. The proliferation at both stages is determined
using ATP bioluminescence technology. The results using busulphan and daunorubicin are
shown in Figs. 9A and 9B, respectively. The effect of busulphan (Fig. 9A) on HPP-SP 1
demonstrates partial cytotoxicity to the stem cells and the presence of residual stem cells.
However, when the treated cells are removed from primary culture and placed into secondary
cultured to reveal their expansion potential, there are few residual cells that are available for
expansion and the high doses used in the primary culture eradicated any remaining cells. There
was also little change in the IC50 values. This indicates that busulphan continued to act on
primitive stem cells leaving no residual stem cells (secondary culture results minus primary
culture results) for possible repopulation. Daunorubicin (Fig. 9B) is highly toxic to stem cells
with an IC50 value in the nanomolar range compared to the micromolar range for busulphan.
At low doses of daunorubicin, residual stem cells would be available, but secondary culture
demonstrates that both these and the residual cells have increased their sensitivity by approx.
3 fold, indicating that repeated drug administration would incur increased sensitivity of the
stem cells to the drug.
Figure 9. Assessing Residual Stem Cell Activity and Change in Stem Cell Sensitivity to Agents by Measuring the Re‐
sponse of Primitive Stem Cells in a Two-Step Secondary Re-Plating In Vitro Assay.
6.5. Stem cells and drug-drug interactions
Drug-drug interaction (DDI) can lead to dangerous consequences if not investigated properly.
Traditionally, DDI are investigated using cultured hepatocytes since the liver is the organ
primarily responsible for detoxification. The main enzymes investigated during DDI studies
are those of the cytochrome P450 (CYP450) system present in the endoplasmic reticulum of
the cells. CYP450 enzymes are present not only in hepatocytes, but in virtually all cells. There
are a large number of CYP450 enzymes and assays are available for many of these. Depending
on the drug or compound, one or more CYP450 enzymes can be induced or inhibited [43,44].
The response by different enzymes provides an indication as to whether an interaction between
different drugs will occur. However, measurement of CYP450 activities does not indicate a
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response at the cellular level. To investigate this, we developed an assay in which drugs could
be titrated against each other to determine potential DDI on stem cells.
Figure 10. Examples of Drug-Drug Interactions at the Stem Cell Level
Figure 10A shows the response when verapamil is titrated against cyclosporin A, while Fig.
10B shows the effect when cyclosporin A is titrated against verapamil. Both drugs inhibit 3A4
CYP450 enzyme. Individually, both drugs are cytotoxic to CFC-GEMM 1 stem cells. However,
when titrated against each other, cytotoxicity may be observed initially, but may be followed
by an opposite effect at higher doses. The cells appear to overcome the inhibitory effects. In
terms of DDI, this would indicate that one or other drug is present at concentrations that could
cause serious harm to the patient. This unusual dose response behavior produces a U-shaped
or inverted dose response curve that has been observed for many compounds, including
dopamine [45] and endostatins [46]. Although often attributed to solubility, these effects
appear to be pharmacologically and physiologically important, but in most cases, the mecha‐
nism is not understood. This is the first indication that DDI can occur at the stem cell level.
Considering the importance of assessing toxicity to stem cells and the predictive value afforded
by these cells, it is obvious that more has to be learnt before the consequences of these reactions
on a stem cell system can be understood.
6.6. Circadian rhythm and stem cells
One of the most interesting aspects of drug treatment is the field of chronotherapy; the
administration of drugs in accordance with circadian rhythms. Although studied for decades,
the role of circadian rhythms to reduce toxicity and improve drug efficacy has been largely
ignored by the biopharmaceutical industry. The primary reason for this is because chrono‐
therapeutic studies are difficult, time-consuming and expensive to perform. Nevertheless,
many areas of chronotherapy, especially using anti-cancer drugs. have proved to be successful
[47-49]. Many cellular functions are dependent upon circadian rhythms. It is not the purpose
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of this section to describe or even summarize this field. The intention is to instead provide an
example in which the circadian rhythm of cells, especially hematopoietic stem cells [50-52],
can be used to predict the best time of day to administer an anti-cancer drug, which in this
case, is 5-fluorouracil (5-FU) [38].
These studies were performed using normal peripheral blood mononuclear cells. Blood was
obtained from the same donor every 4 hours over a 24 hours period. The MNCs were fractio‐
nated at each time point and cryopreserved into aliquots. Prior to cryopreservation, an aliquot
of fresh cells was used to measure the proliferation ability of hematopoietic stem cells (CFC-
GEMM 1), erythropoietic progenitor cells (burst-forming units – erythroid, BFU-E), GM-CFC
and megakaryopoietic progenitor cells (megakaryopoietic colony-forming cells, Mk-CFC) at
each time point using HALO. After collection of the cells, an aliquot from each time point was
thawed and the circadian rhythms compared to fresh cells. A cosinor curve fitting analysis
was performed to produce all the circadian rhythms shown in Fig. 11 [53]. The results for
hematopoietic stem cells (Fig. 11A) and all progenitor cells (not shown) demonstrate that even
after cryopreservation, the cell populations maintain their circadian rhythm. This was a
prerequisite to use cryopreserved cells for the remainder of the study.
A.
B.
C.
Figure 11. Using the Circadian Rhythm of Hematopoietic Stem Cells to Predict the Best Time of Day to Administer 5-
Fluorouracil to Reduce Toxicity and Improve Efficacy of the Drug.
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For each time point, cells were thawed and treated with 5-FU at six doses to measure the
response of CFC-GEMM 1, BFU-E, GM-CFC and Mk-CFC. The slope of each negative sigmoi‐
dal dose response curve was then calculated from the 4-parameter logistic curve fit. The dose
response slope values were then analyzed by cosinor analysis for each time point and for each
cell population to obtain the circadian rhythms as a function of 5-FU treatment. The results are
shown in Fig. 10B. Each of the hematopoietic cell populations exhibited its own circadian
rhythm in response to 5-FU. When these circadian rhythms were correlated with either the
continuous infusion of 5-FU that is normally used to treat patients and that of chronomodu‐
lated infusion of 5-FU as reported by Dogliotti and colleagues in 1998 [54], the results shown
in Fig. 10C were obtained. For each of the administration types, the percent overall patient
response rate, toxicity and tumor response are shown. These were overlaid onto the circadian
rhythm for the CFC-GEMM 1 stem cell response to 5-FU and demonstrated that the lowest
toxicity and highest overall and tumor response occurred when 5-FU was administered in a
chronomodulated manner in the early morning hours rather than at any other time of the day.
The nadir of the CFC-GEMM 1 circadian rhythm to 5-FU occurred at 14:00 hours in the
afternoon. This was approximately the same time at which the highest toxicity to 5-FU was
found. As expected, these results did not correlate nearly as well for the hematopoietic
progenitor cells. In addition, the results clearly demonstrate that the potential for toxicity can
be dramatically reduced if the circadian rhythm of the target cells is taken into account. From
the brief description here, it follows that to ascertain the best time of day to administer a drug
a considerable amount of work must be undertaken. The question is whether the patient
response and well-being outweigh the time and cost to perform these types of studies.
7. Conclusions and future trends
To use in vitro stem cell assays to predict potential toxicity to the hematopoietic system, and
any stem cell system for that matter, knowledge of the biology, physiology, regulation and
response is required for an in vitro to in vivo concordance to be justified. This concordance plays
an integral role in predicting toxicity since it allows for in vitro surrogate assays to be used in
place of animals and therefore comply with the principle of the 3Rs (replacement, reduction
and refinement) [55]. More importantly, to allows extrapolation to the human situation.
Previous literature on stem cell and hematopoietic research demonstrates that in vitro assays
show a high concordance with in vivo data. Using the HALO platform, Olaharski et al.
demonstrated an in vitro to in vivo concordance of greater than 80% [56]. This high degree of
concordance provides the basis to predict the response of the lympho-hematopoietic and other
stem cell systems to potential toxic insults. This has been described previously [32], but it is
worth reiterating some of these paradigms. First, virtually any compound can be toxic to stem
cells. Second, toxicity to the most primitive, definitive stem cells will affect all cells of the
system. Third, since stem cells only proliferate and proliferation occurs prior to differentiation,
stem cell cytotoxicity will affect all downstream cell types. Fourth, if more than one cell lineage
is affected by toxicity, the target is not the cells that constitute the lineages, but the stem cells
producing the lineages. Finally, stem cells are more sensitive to toxicity than the progenitor
Stem Cell Predictive Hemotoxicology
http://dx.doi.org/10.5772/54430
101
cells. When considering using stem cells to predict potential toxicity, at least two considera‐
tions need to be taken into account. The first is the primitiveness of the stem cell population
being measured, while the second is variation between human donors. The former will
depend, among other things, upon the ability and sensitivity of the assay to detect specific
stem cell populations and the latter will be dependent upon the state and demographics of the
donors that can, in turn, affect the stem cells. Both are difficult to control, but can provide a
more realistic view.
Based on these paradigms, it is worth briefly considering how the non-definitive stem cells
systems (Fig. 1), ES and iPS cells, fit into predictive stem cell toxicity testing. At the present
time, these cells are used to produce functionally, mature lineage-specific cells such as
hepatocytes, cardiomyocytes and neurons. These and other cell types can be produced in larger
numbers and presumably at a lower cost than their primary counterparts. Embryonic stem
cells are used as an in vitro developmental toxicity model to predict teratogenicity. The use of
ES and/or iPS cells for definitive stem cell system toxicity testing is certainly on the horizon. It
should be remembered however, that even to produce functionally, mature hepatocytes,
cardiomycytes and other cells, the ES and iPS cells must pass through the definitive stem cell
compartment specific for the cells being produced. In other words, the ES and iPS cells should
produce an organization analogous to that shown in Fig. 2. If this transpires, then the face of
toxicity testing, and stem cell toxicity testing in particular, as well as many other applications,
could significantly change the face of biological and toxicological research in the future.
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